Your browser is no longer supported. Please, upgrade your browser.
ALXO ALX Oncology Holdings Inc. daily Stock Chart
ALX Oncology Holdings Inc.
Index- P/E- EPS (ttm)-3.47 Insider Own2.60% Shs Outstand37.82M Perf Week4.58%
Market Cap1.48B Forward P/E- EPS next Y-1.89 Insider Trans0.00% Shs Float22.14M Perf Month-9.96%
Income-34.40M PEG- EPS next Q-0.36 Inst Own- Short Float0.84% Perf Quarter-
Sales3.70M P/S399.36 EPS this Y-33.70% Inst Trans- Short Ratio1.00 Perf Half Y-
Book/sh- P/B- EPS next Y-12.50% ROA- Target Price56.40 Perf Year-
Cash/sh2.59 P/C15.06 EPS next 5Y- ROE- 52W Range28.01 - 52.00 Perf YTD30.23%
Dividend- P/FCF- EPS past 5Y- ROI29.40% 52W High-24.87% Beta-
Dividend %- Quick Ratio13.00 Sales past 5Y- Gross Margin9.10% 52W Low39.49% ATR3.96
Employees19 Current Ratio13.00 Sales Q/Q-50.00% Oper. Margin- RSI (14)49.98 Volatility8.42% 9.86%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.43 Prev Close39.22
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume186.92K Price39.07
Recom1.80 SMA20-3.76% SMA50-0.72% SMA200-0.72% Volume80,242 Change-0.38%
Aug-11-20Initiated Piper Sandler Overweight $55
Aug-11-20Initiated Jefferies Buy $50
Aug-11-20Initiated Credit Suisse Outperform $53
Aug-11-20Initiated Cantor Fitzgerald Overweight $64
Sep-22-20 07:00AM  
Sep-17-20 07:00AM  
Sep-08-20 07:00AM  
Aug-27-20 04:05PM  
Jul-21-20 04:05PM  
Jul-17-20 04:17PM  
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic used for the treatment of myelodysplastic syndromes and acute myeloid leukemia, as well as a range of solid tumor indications, including head and neck squamous cell and human epidermal growth factor receptor 2 positive gastric/gastroesophageal junction carcinoma. The company was founded in 2015 and is based in Burlingame, California.